Biogen Inc. Stock
€116.80
Your prediction
Biogen Inc. Stock
Pros and Cons of Biogen Inc. in the next few years
Pros
Cons
Performance of Biogen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | 2.370% | 2.232% | 13.729% | -45.190% | -18.917% | -36.947% | -57.019% |
| Elanco Animal Health Inc. | 3.580% | 2.484% | 43.243% | -27.209% | 5.733% | -45.479% | -42.406% |
| Johnson & Johnson | 1.240% | -0.293% | 0.162% | 1.130% | -2.200% | -17.852% | 4.262% |
| Pfizer Inc. | 1.480% | -0.847% | 1.865% | -22.586% | -19.275% | -59.007% | -32.333% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.
Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.
Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.
Comments
News
Biogen Stock Is Mutating Into a Value Play
Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology
Biogen Stock: Mixed Q4 Results Spark Strategic Shift
Biogen's fourth quarter 2024 performance presents a complex picture for investors, with revenue climbing 2.9% to $2.46 billion and adjusted earnings per share reaching $3.44, surpassing market
Biogen (BIIB) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q4 2024 Earnings CallFeb 12, 2025, 8:30 a.m. ET
Operator
Source Fool.com
